ANX Mast Therapeutics, Inc.

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced today that it completed the previously announced sale of 14,545,000 shares of its common stock in a registered direct offering at a price of $2.75 per share. The offering raised gross proceeds of approximately $40 million and net offering proceeds of approximately $37.3 million, after deducting commissions and estimated offering fees and expenses. All of the shares were sold by ADVENTRX Pharmaceuticals. The shares were offered under the Company's effective shelf registration statement on Form S-3. ThinkEquity Partners LLC acted as lead placement agent and Fortis Securities LLC acted as co-placement agent in connection with this transaction. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing low development risk pharmaceuticals for cancer and infectious disease that enhance the efficacy and/or safety of existing therapies. Forward Looking Statements ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, +1-858-552-0866

Copyright